Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2335-2341

  Schmitt Sody, Marcus ^a   Strieth, Sebastian ^a   Krasnici, Senat ^a   Sauer, Birgitta ^b   Schulze, Brita ^b   Teifel, Michael ^b   Michaelis, Uwe ^b   Naujoks, Kurt ^b   Dellian, Marc ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Munich Biotech AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPAC; LIPOSOME; PACLITAXEL; RHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; ENCAPSULATION; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HAMSTER; LYMPH NODE METASTASIS; MALE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CRICETINAE; LIPOSOMES; LYMPHATIC METASTASIS; MALE; MESOCRICETUS; MICROSCOPY, FLUORESCENCE; NEOPLASMS, EXPERIMENTAL; PACLITAXEL;

EID: 0037499918     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Denekamp, J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer, 45: 136-139, 1982.
2. Denekamp, J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur. J. Clin. Investig., 29: 733-736, 1999.
3. Rowinsky, E. K., and Donehower. R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
4. Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., and Doenicke, A. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions, 7: 63-67, 1977.
5. Treat, J., Damjanov, N., Huang, C., Zrada, S., and Rahman, A. Liposomal-encapsulated chemotherapy: preliminary results of a Phase I study of a novel liposomal paclitaxel. Oncology (Huntingt.), 15: 44-48, 2001.
6. Cabanes, A., Briggs, K. E., Gokhale, P. C., Treat, J. A., and Rahman, A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J. Oncol., 12: 1035-1040, 1998.
7. Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., and McDonald, D. M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Investig., 101: 1401-1413, 1998.
8. Damen, E. W., Wiegerinck, P. H., Braamer, L., Sperling, D., de Vos, D., and Scheeren, H. W. Paclitaxel esters of malic acid as prodrugs with improved water solubility. Bioorg. Med. Chem., 8: 427-432, 2000.
9. Sharma, A., and Straubinger, R. M. Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. Pharm. Res. (N. Y.), 11: 889-896, 1994.
10. Asaishi, K., Endrich, B., Goetz, A., and Messmer, K. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res., 41: 1898-1904, 1981.
11. Endrich, B., Hammersen, F., Goetz, A., and Messmer, K. Microcirculatory blood flow, capillary morphology and local oxygen pressure of the hamster amelanotic melanoma A-Mel-3. J. Natl. Cancer Inst. (Bethesda), 68: 475-485, 1982.
12. Fortner, J., Mahy, M., and Schrodt, G. Transplantable tumors of the Syrian (golden) hamster. Part I: tumors of the alimentary tract, endocrine glands and melanomas. Cancer Res., 21: 161-198, 1961.
13. Leunig, M., Richert, C., Gamarra, F., Lumper, W., Vogel, E., Jocham, D., and Goetz, A. E. Tumour localisation kinetics of photofrin and three synthetic porphyrinoids in an amelanotic melanoma of the hamster. Br. J. Cancer, 68: 225-234, 1993.
14. Weiss, N., Delius, M., Gambihler, S., Dirschedl, P., Goetz, A., and Brendel, W. Influence of the shock wave application mode on the growth of A-Mel 3 and SSK2 tumors in vivo. Ultrasound Med. Biol., 16: 595-605, 1990.
15. Li, C., Yu, D., Inoue, T., Yang, D. J., Milas, L., Hunter, N. R., Kim, E. E., and Wallace, S. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs, 7: 642-648, 1996.
16. Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., and Martinez, A. Drug delivery systems: water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem., 39: 424-431, 1996.
17. Pendri, A., Conover, C. D., and Greenwald, R. B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anticancer Drug Des., 13: 387-395, 1998.
18. Safavy, A., Raisch, K. P., Khazaeli, M. B., Buchsbaum, D. J., and Bonner, J. A. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem., 42: 4919-4924, 1999.
19. Krasnici, S., Werner, A., Eichhorn, M. E., Schmitt-Sody, M., Pahernik, S., Sauer, B., Schulze, B., Teifel, M., Michaelis, U., Naujoks, K., and Dellian, M. Effect of the surface charge of liposomes on their uptake by angiogenic tumour vessels. Int. J. Cancer, 5: 561-567, 2003.
20. Jain, R. K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med., 4: 655-657, 1998.
21. Vincent, S., DePace, D., and Finkelstein, S. Distribution of anionic sites on the capillary endothelium in an experimental brain tumor model. Microcirc. Endothelium Lymphatics, 4: 45-67, 1988.
22. McLean, J. W., Fox, E. A., Baluk, P., Bolton, P. B., Haskell, A., Pearlman, R., Thurston, G., Umemoto, E. Y., and McDonald, D. M. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am. J. Physiol., 273: H387-H404, 1997.
23. Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., Torchilin, V. P., and Munn, L. L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res., 62: 6831-6836, 2002.
24. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Wash. DC), 275: 547-550, 1997,
25. Griggs, J., Metcalfe, J. C., and Hesketh, R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol., 2: 82-87, 2001.
26. Blakey, D. C., Westwood, F. R., Walker, M., Hughes, G. D., Davis, P. D., Ashton, S. E., and Ryan, A. J. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res., 8: 1974-1983, 2002.
27. Halin, C., Zardi, L., and Neri, D. Antibody-based targeting of angiogenesis. News Physiol. Sci., 16: 191-194, 2001.
28. Dass, C. R. Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J. Cancer Res. Clin. Oncol., 128: 177-181, 2002.
29. Dellian, M., Walenta, S., Gamarra, F., Kuhnle, G. E., Mueller-Klieser, W., and Goetz, A. E. High-energy shock waves enhance hyperthermic response of tumors: effects on blood flow, energy metabolism, and tumor growth. J. Natl. Cancer Inst. (Bethesda), 86: 287-293, 1994.
30. Weidner, N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol., 147: 9-19, 1995.
31. Rak, J., Filmus, J., and Kerbel, R. S. Reciprocal paracrine interactions between tumour cells and endothelial cells: the "angiogenesis progression" hypothesis. Eur. J. Cancer, 32A: 2438-2450, 1996.